Bayer Aktiengesellschaft Price to Free Cash Flow Ratio 2010-2024 | BAYRY

Historical price to free cash flow ratio values for Bayer Aktiengesellschaft (BAYRY) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Bayer Aktiengesellschaft Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2024-12-27 4.98 inf
Sector Industry Market Cap Revenue
Medical Large Cap Pharma $22.635B $51.553B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly and Company (LLY) US $828.397B 67.21
Novo Nordisk A/S (NVO) DK $395.262B 26.77
Johnson & Johnson (JNJ) US $390.756B 16.25
AbbVie Inc. (ABBV) US $356.743B 19.97
Roche Holding AG (RHHBY) CH $264.174B 0.00
Merck & Co., Inc. (MRK) US $226.402B 11.72
Novartis AG (NVS) CH $223.511B 14.00
Pfizer Inc. (PFE) US $149.042B 8.46
Sanofi (SNY) $138.211B 13.09
Innoviva, Inc. (INVA) US $1.132B 9.42